Clinical Trial Update: Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk [Phase 4]

View source ↗

Summary

Phase 4 trial assessing switching from twice-daily tacrolimus to once-daily formulation and its impact on cardiovascular risk in immunosuppressed patients, incl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Immunosuppression
• Kidney Transplant Rejection Prevention

Drugs mentioned

• Tacrolimus (Tacrolimus)

Snippet

Sponsor: University of Saskatchewan | Conditions: Immunosuppression, Cardiovascular Diseases | Phase 4 | Status: COMPLETED